HALO — HALOZYME THERAPEUTICS, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 1159036 ·
Last close
$113.90
Market Cap
$12.93B
52W High
$116.85
52W Low
$61.23
ADV30
2,092,757
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 480,999,000 401,828,000 287,654,000 229,913,000 2,577,408,000 163,138,000 2,433,865,000
Mar 2026 376,708,000 297,470,000 184,517,000 150,049,000 2,672,719,000 309,749,000 2,453,083,000
Dec 2025 451,767,000 372,997,000 240,696,000 -141,591,000 2,525,323,000 133,820,000 2,476,509,000
Sep 2025 354,264,000 299,022,000 217,921,000 175,225,000 2,221,232,000 419,665,000 1,717,317,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$818,595,000
Investing CF
$-605,719,000
Financing CF
$-110,751,000
CapEx
$-300,142,000
Dividends Paid
—
Buybacks
$-288,883,000
EPS Diluted TTM
$3.35
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$151,259,000
Inventory
$137,135,000
Receivables
$455,827,000
ST Investments
$67,865,000
EBIT TTM
$603,641,000
Pretax Income TTM
$583,338,000
Interest Exp TTM
$20,303,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,663,737,984
EBITDA
$1,050,688,000
Free Cash Flow
$337,308,640
Enterprise Value
$14,114,515,968
Total Cash
$231,003,008
Total Debt
$2,178,533,120
Shares Out
113,498,000
Trailing EPS
$3.41
Book Value
$1.26
ROE
173.7%
ROA
25.5%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,396,611,000 802,593,000 316,889,000 2,525,323,000 2,476,509,000 48,814,000 651,558,000
Dec 2024 1,015,324,000 551,475,000 444,091,000 2,063,477,000 1,699,656,000 363,821,000 479,064,000
Dec 2023 829,253,000 337,574,000 281,594,000 1,733,270,000 1,649,462,000 83,808,000 388,571,000
Dec 2022 660,116,000 267,531,000 202,129,000 1,841,511,000 1,671,713,000 169,798,000 240,110,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$979,954,000
NetIncome TTM
$398,577,000
OpCashFlow TTM
$0
Assets (Latest)
$2,525,323,000
Forward EPS
$10.39

Max Pain — expiry 2026-12-18

max pain strike: $80.00 · spot: $113.90 · call oi: 4,305 · put oi: 1,203
Expected Move to 2026-12-18: ±$14.90 (13.08%) — implied range $99.00 – $128.80 · ATM straddle on $115.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TWST Twist Bioscience Corp $12.12B $182.83 —
NBIX NEUROCRINE BIOSCIENCES INC $14.07B $138.40 —
EXEL EXELIXIS, INC. $14.41B $58.16 —
TECH BIO-TECHNE Corp $11.39B $72.61 —
RGEN REPLIGEN CORP $10.70B $189.68 —

News headlines (Yahoo Finance, 1h cache)

Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?
2026-09-23 09:30 · Yahoo
Halozyme (HALO) Just Made A $1.3B Bet On Itself
2026-09-22 02:57 · Yahoo
Halozyme Therapeutics (HALO) Proposes $1.05B in Convertibles. Is More Time Worth the Cost?
2026-09-21 00:27 · Yahoo
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
2026-09-18 03:20 · Yahoo
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
2026-09-16 20:30 · Yahoo
Halozyme Investor Conferences Put ENHANZE and Expanded Drug Delivery Portfolio in Focus
2026-09-02 14:40 · Yahoo
Halozyme to Participate at Upcoming Investor Conferences
2026-09-02 12:30 · Yahoo
Why Women-Run Companies Deserve a Place in Your Portfolio
2026-09-24 16:42 · Yahoo
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
2026-09-23 14:31 · Yahoo
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now
2026-09-23 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.